Risk-Adapted Therapy Improves Survival in Pediatric Acute Myeloid Leukemia

Refining Risk Stratification in Pediatric Acute Myeloid Leukemia

The clinical management of pediatric acute myeloid leukemia (AML) has increasingly shifted toward precision medicine, driven by an evolving understanding of the disease's genetic landscape and the integration of molecular biomarkers [1, 2, 3]. While intensive chemotherapy remains the backbone of treatment, the ability to accurately identify which children require treatment escalation, such as allogeneic hematopoietic stem cell transplantation (the replacement of a patient's hematopoietic system with healthy donor cells), is critical for balancing curative intent with the risk of therapy-related toxicity [4, 5]. Central to this effort is the monitoring of measurable residual disease (a highly sensitive technique using flow cytometry or molecular assays to detect sub-microscopic levels of leukemia cells), which has emerged as a primary independent prognostic indicator [6, 7]. In a recent analysis of 136 pediatric patients, a reduction of less than 3-log in transcript levels after induction chemotherapy predicted an inferior prognosis (p < 0.05), reinforcing the need for early response-based intervention [7]. Despite these advances, optimizing induction agents and refining thresholds for risk-adapted consolidation remain active areas of clinical investigation [8, 9]. Findings from the AIEOP-AML-2013 trial involving 371 patients demonstrated that integrated genetic and response-based stratification achieved a morphological complete remission rate of 92%, highlighting the efficacy of contemporary risk-stratified protocols [10].

Trial Design and Risk-Based Allocation

The AIEOP-AML-2013 trial enrolled 371 patients between June 2015 and June 2022, with a final data cut-off for analysis on February 1, 2024. The study evaluated the efficacy of a refined patient stratification system and a randomized second induction phase. Patients were assigned to one of three categories: standard-risk (SR), intermediate-risk (IR), or high-risk (HR). This stratification was primarily based on specific genetic criteria and a centralized assessment of multiparametric flow-cytometry measurable residual disease (MFC-MRD), a laboratory method that uses fluorescent markers to identify and quantify minute populations of leukemic cells that persist after therapy. Under these refined criteria, the researchers allocated 19.5% of patients to the SR group, 22% to the IR group, and 58.5% to the HR group. All enrolled patients received a uniform first induction course consisting of idarubicin, cytarabine, and etoposide (ICE). Following this initial treatment, patients in the IR and HR groups underwent randomization to receive either a second course of ICE or the FLA-My regimen, which consists of fludarabine, cytarabine, and liposomal doxorubicin. This randomization was designed to determine if the FLA-My scheme offered a therapeutic advantage over repeating the standard ICE induction for patients with higher-risk disease profiles. Consolidation strategies were strictly risk-adapted to balance treatment intensity with the risk of relapse. All patients in the HR group, along with IR patients who possessed an HLA-compatible sibling (a donor whose human leukocyte antigens match the patient's, minimizing the risk of graft rejection), were consolidated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). The remaining IR patients and all patients in the SR group were consolidated with chemotherapy only. This approach ensured that the most intensive interventions were reserved for those with the highest risk of treatment failure based on their genetic profile and early response to induction, potentially sparing lower-risk children from the long-term sequelae of transplant.

Survival Outcomes and Comparative Efficacy

The AIEOP-AML-2013 trial demonstrated substantial improvements in survival metrics compared to the historical benchmarks established in the previous Italian national trial, AIEOP-AML-2002/01. In that earlier study, the 3-year overall survival (OS) was 72.3% and the 3-year event-free survival (EFS) was 59.1%. By contrast, the current study achieved a 3-year probability of OS of 83.9% and a 3-year probability of EFS of 68.5%. These improvements in both OS and EFS were statistically significant, with a p-value of 0.001 when compared directly to the AIEOP-AML-2002/01 study. These data suggest that the refined stratification and risk-adapted protocols implemented in the 2013 trial successfully enhanced clinical outcomes for pediatric patients with acute myeloid leukemia. Survival outcomes remained high across all risk categories, though they varied according to the intensity of the disease profile. The 3-year OS for patients in the standard-risk (SR) group reached 97.0%, while the intermediate-risk (IR) group showed a 3-year OS of 84.2%. Patients classified as high-risk (HR) had a 3-year OS of 79.4%. The differences in overall survival across these three risk groups were statistically significant, with a p-value of 0.01. This gradient in survival confirms that while the current protocol provides excellent outcomes for low-risk patients, the high-risk population continues to face greater clinical challenges despite the use of intensified consolidation strategies like allogeneic hematopoietic stem cell transplantation. A key component of the trial was the randomization of intermediate-risk and high-risk patients to receive either a second course of idarubicin, cytarabine, and etoposide (ICE) or the fludarabine, cytarabine, and liposomal doxorubicin (FLA-My) regimen. The researchers found that the probability of EFS did not differ in IR and HR patients randomized to receive either a second ICE or the FLA-My scheme course. Specifically, the data indicated that FLA-My did not offer any advantage over repeating a second ICE as a second induction course. For the practicing clinician, this finding suggests that the addition of liposomal doxorubicin in the FLA-My regimen does not provide superior protection against relapse or treatment failure compared to the established ICE protocol during the second induction phase, allowing for more standardized induction choices.

Safety Profile and Prognostic Indicators

The safety profile of the AIEOP-AML-2013 protocol was characterized by low early mortality despite the intensive nature of the chemotherapy regimens. Among the 371 patients enrolled in the trial, twenty-six children (7%) experienced primary induction failure, defined as the inability to achieve complete remission after the initial treatment phases. However, treatment-related mortality during the early stages of therapy was minimal, as only 3 patients died during the 2 induction courses. This low rate of early death suggests that the supportive care measures and monitoring protocols utilized in the trial were effective in managing the acute toxicities associated with the idarubicin, cytarabine, and etoposide (ICE) or fludarabine, cytarabine, and liposomal doxorubicin (FLA-My) regimens. Beyond the induction phase, the researchers tracked long-term safety and disease control. The cumulative incidence of 3-year non-relapse mortality in continuous complete remission was 6.8%, a figure that reflects the risks associated with intensive consolidation, including allogeneic hematopoietic stem cell transplantation in high-risk and certain intermediate-risk patients. In terms of disease control, the three-year cumulative incidence of relapse was 18.9%. These figures provide a clear picture of the balance between treatment-related risks and the efficacy of the risk-adapted strategy in preventing leukemic return. The study also reinforced the critical role of measurable residual disease (the small number of cancer cells that remain in the body after treatment, which cannot be seen by standard microscopic examination) as a primary prognostic indicator. The researchers determined that levels of measurable residual disease after the 1st and 2nd induction course strongly influenced the event-free survival probability. This finding underscores the clinical importance of centralized assessment using multiparametric flow-cytometry to monitor treatment response. For the clinician, these results confirm that the depth of response after early induction cycles is a reliable predictor of long-term outcomes and remains a cornerstone for refining therapeutic intensity in pediatric acute myeloid leukemia, providing a biological benchmark to guide the necessity of transplantation.

References

1. Döhner H, Estey EH, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016. doi:10.1182/blood-2016-08-733196

2. Chaer FE, Hourigan CS, Zeidan AM. How I Treat AML in 2023 Incorporating the Updated Classifications and Guidelines. Blood. 2023. doi:10.1182/blood.2022017808

3. Arber DA, Orazi A, Hasserjian RP, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016. doi:10.1182/blood-2016-03-643544

4. Inyushkina E, Gunyakov S, Bogucharskii AV, Stepanova VO. Treatment Efficacy for Pediatric Acute Myeloid Leukemias: Results of a Single-Center Trial. Clinical oncohematology. 2026. doi:10.21320/2500-2139-2026-19-2-142-151

5. Grimwade D, Walker HM, Oliver F, et al. The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial. Blood. 1998. doi:10.1182/blood.v92.7.2322

6. Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018. doi:10.1182/blood-2017-09-801498

7. Zhang L, Yi M, Chen X, et al. Measurable residual disease dynamics holding prognostic significance in pediatric patients with RUNX1::RUNX1T1-positive AML: results from AML-CAMS serial trials.. Leukemia & lymphoma. 2025. doi:10.1080/10428194.2025.2548966

8. Kapp-Schwoerer S, Weber D, Corbacioglu A, et al. Assessment of Treatment Effects By Measurable Residual Disease Monitoring in NPM1-Mutated AML Patients Randomized for Gemtuzumab-Ozogamicin (GO) within the AMLSG 09-09 Trial of the German-Austrian AML Study Group (AMLSG). Blood. 2018. doi:10.1182/BLOOD-2018-99-114648

9. Tomizawa D, Tsujimoto S, Tanaka S, et al. A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for non-low-risk patients (JPLSG-AML-20).. Japanese journal of clinical oncology. 2022. doi:10.1093/jjco/hyac105

10. Locatelli F, Buldini B, Pigazzi M, et al. Final Results of the AIEOP (Associazione Italiana Ematologia/Oncologia Pediatrica) AML 2013 Prospective Randomized Trial in Childhood Acute Myeloid Leukemia (AML). Blood. 2023. doi:10.1182/blood-2023-188682